NeoGenomics, Inc. Hits New 52-Week High of $15.20

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 15.20 on July 1, 2026. This achievement marks a notable increase from its 52-week low of USD 4.72, reflecting a 12.39% performance over the past year, although it trails behind the S&P 500's performance of 20.74% during the same period. With a market capitalization of USD 933 million, NeoGenomics operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reveal a debt-to-equity ratio of 0.22, indicating a relatively low level of debt compared to equity. However, it is important to note that NeoGenomics is currently loss-making, as reflected by its negative return on equity of -8.39%. The stock does not offer a dividend yield, and its price-to-book ratio stands at 1.12, suggesting a valuation that may be of interest to market participants. This recent price movement underscores the evolving dynamics within the biotechnology sector.